Preclinical studies have revealed that combination of PI3K inhibitors with HDAC inhibitors (HDACIs) show promising antitumour activity against solid tumours, including prostate cancer.19, 20, 21, 22. This evidence concerns the gene HDAC9 and prostate cancer.